Literature DB >> 24471890

Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles.

Shougang Jiang1, Xianfeng Gong, Xiuhua Zhao, Yuangang Zu.   

Abstract

CONTEXT: Docetaxel is now a major antitumor drug in clinical use for the treatment of a variety of tumors. The ethanol/Tween 80 solvent required in the formulation to increase the docetaxel solubility is at least partly responsible for the hypersensitivity reaction, decreased uptake by tumor tissue, and increased exposure to other body compartments.
OBJECTIVE: The present study was aimed at developing hydrosoluble DTX-FA-HSANPs targeting tumor cells and to investigate antitumor activities of the nanoparticles.
MATERIALS AND METHODS: The DTX-HSANPs were prepared using a desolvation technique and the carboxylic groups of NHS-folate were conjugated with the amino groups of the human serum albumin nanoparticles, and studied their size and zeta potential, drug loading efficiency, surface morphology, release properties in vitro, and antitumor activities.
RESULTS: The spherical nanoparticles obtained were negatively charged with a zeta potential of about -30 mV and characterized around 150 nm with a narrow size distribution. Drug loading efficiency was approximately 17.2%. The folate-decorated nanoparticles targeted a human hepatoma cell line effectively. The in vitro drug release of DTX-FA-HSANPs in the first 96 h corresponded with the following equation: Q = 18.87851 - 0.13866t + 0.21276t² - 0.00704t³ + 0.0000847854t⁴ - 0.00000034991t⁵ (R² = 0.98155). Moreover, the in vitro antitumor activities of DTX-FA-HSANPs were close to the activities of the positive control (docetaxel). The in vivo inhibition ratios of DTX-FA-HSANPs and docetaxel were 66.2% and 59.5%, respectively, at a dose of 5 mg/kg. DISCUSSION AND
CONCLUSION: In light of the observed antitumor activities, it would be of considerable interest to collect sufficient data for the clinical application of docetaxel-loaded nanoparticles.

Entities:  

Keywords:  Antitumor activities; docetaxel; folate; human serum albumin; nanoparticles

Mesh:

Substances:

Year:  2014        PMID: 24471890     DOI: 10.3109/10717544.2013.879964

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  6 in total

Review 1.  Insight into nanoparticle cellular uptake and intracellular targeting.

Authors:  Basit Yameen; Won Il Choi; Cristian Vilos; Archana Swami; Jinjun Shi; Omid C Farokhzad
Journal:  J Control Release       Date:  2014-06-28       Impact factor: 9.776

Review 2.  Protein Nanoparticles: Uniting the Power of Proteins with Engineering Design Approaches.

Authors:  Nahal Habibi; Ava Mauser; Yeongun Ko; Joerg Lahann
Journal:  Adv Sci (Weinh)       Date:  2022-01-25       Impact factor: 16.806

3.  Albumin Binds Doxorubicin via Self-Assembling Dyes as Specific Polymolecular Ligands.

Authors:  Anna Jagusiak; Katarzyna Chłopaś; Grzegorz Zemanek; Izabela Kościk; Paweł Skorek; Barbara Stopa
Journal:  Int J Mol Sci       Date:  2022-05-01       Impact factor: 6.208

4.  Tumor targeting with docosahexaenoic acid-conjugated docetaxel for inhibiting lung cancer metastasis to bone.

Authors:  Shougang Jiang; Zhiguo Liu; Lei Wu; Yingjie Yuan; Yan Hu; Xingyao Zhang; Liang Wei; Yuangang Zu
Journal:  Oncol Lett       Date:  2018-06-28       Impact factor: 2.967

5.  Polyunsaturated fatty acid-based targeted nanotherapeutics to enhance the therapeutic efficacy of docetaxel.

Authors:  Thiruganesh Ramasamy; Pasupathi Sundaramoorthy; Hima Bindu Ruttala; Yongjoo Choi; Woo Hyun Shin; Jee-Heon Jeong; Sae Kwang Ku; Han-Gon Choi; Hwan Mook Kim; Chul Soon Yong; Jong Oh Kim
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

6.  Albumin-bioinspired iridium oxide nanoplatform with high photothermal conversion efficiency for synergistic chemo-photothermal of osteosarcoma.

Authors:  Wenguang Gu; Tao Zhang; Junsheng Gao; Yi Wang; Dejian Li; Ziwen Zhao; Bo Jiang; Zhiwei Dong; Hui Liu
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.